PRESTALIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6696481 | ADHERA | Salt of perindopril and pharmaceutical compositions containing it |
Apr, 2023
(1 year, 18 days ago) | |
| US7846961 | ADHERA | α crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it |
Oct, 2029
(5 years from now) | |
Prestalia is owned by Adhera.
Prestalia contains Amlodipine Besylate; Perindopril Arginine.
Prestalia has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Prestalia are:
- US6696481
Prestalia was authorised for market use on 21 January, 2015.
Prestalia is available in tablet;oral dosage forms.
Prestalia can be used as treatment of hypertension.
The generics of Prestalia are possible to be released after 05 October, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 21, 2018 |
Drugs and Companies using AMLODIPINE BESYLATE; PERINDOPRIL ARGININE ingredient
Market Authorisation Date: 21 January, 2015
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
How can I launch a generic of PRESTALIA before it's drug patent expiration?
More Information on Dosage
PRESTALIA family patents
